32 News by Biotie Therapies

Tip: You can further refine your news selection by topics, departments, countries and industries.

32 News by Biotie Therapies

Tip: You can further refine your news selection by topics, departments, countries and industries.

Biotie announces start of tozadenant Phase 3 Study in Parkinson's disease

22-Jul-2015 - Biotie announces the start of the Phase 3 clinical study of tozadenant, an investigational adenosine A2a receptor antagonist, in patients with Parkinson's disease (PD) experiencing levodopa related end-of-dose "wearing-off".The Phase 3 study (TOZ-PD) is a randomized, double-blind, placebo ...

Parkinson's disease phase III studies tozadenant

Biotie: BTT1023 receives positive opinion for Orphan Drug Designation

19-Feb-2015 - The Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending orphan drug designation for Biotie's BTT1023 drug candidate for the treatment of primary sclerosing cholangitis (PSC). PSC is a chronic and progressive fibrotic ...

monoclonal antibodies Orphan Drug Designation phase II studies

Biotie awarded USD 2 million grant from The Michael J. Fox Foundation

09-Jul-2014 - Biotie Therapies has signed a USD 2 million research contract with The Michael J. Fox Foundation (MJFF) to investigate SYN120 in Parkinson's disease patients with dementia. SYN120 is a dual antagonist of 5-HT6 and 5-HT2a receptors and these two distinct modes of action could result in a unique ...

dementia Parkinson's disease

David Cook appointed Chief Financial Officer of Biotie

07-Jan-2013 - David Cook, 45, has been appointed Chief Financial Officer (CFO) of Biotie Therapies Corp., effective February 25, 2013. He will become a member of the Group's management team and will report to Timo Veromaa, President and Chief Executive Officer. David will be based at the Company's headquarters ...

appointments

Biotie: Tozadenantmeets primary and multiple secondary endpoints in phase 2b study in Parkinson's disease

14-Dec-2012 - Biotie reported top-line data from a Phase 2b study evaluating its adenosine A2a antagonist tozadenant (SYN115) in Parkinson's disease (PD) patients experiencing levodopa related end of dose wearing off. The study met its primary endpoint of a statistically highly significant decrease in 'off' ...

Parkinson's disease phase IIb studies tozadenant

Change in Biotie management

18-Sep-2012 - Biotie's chief financial officer (CFO) Panu Miettinen is leaving the company from 1st November 2012 to pursue other interests. Kristian Rantala (36), M.Sc. (Econ), Vice President, Finance based in Finland has been nominated as the interim CFO. Kristian has been with Biotie for altogether two ...

Heparin-like compounds inhibit breast cancer metastasis to bone

21-May-2012 - Researchers from VTT Technical Research Centre of Finland have in collaboration with the University of Turku, Indiana University and two Finnish companies, Biotie Therapies Corp. and Pharmatest Services Ltd, discovered a novel mechanism regulating the development of breast cancer bone metastases ...

bone metastases breast cancer RNA interference

Biotie and Seikagaku agree to end License Agreement on Biotie's VAP-1 antibody program

02-May-2012 - Biotie Therapies Corp. announced that Biotie and Seikagaku Corporation have agreed to terminate their License Agreement on Biotie's VAP-1 antibody program. The license, under which Biotie had granted Seikagaku exclusive rights for development and commercialization of its VAP-1 monoclonal ...

monoclonal antibodies

Panu Miettinen appointed Chief Financial Officer of Biotie

15-Feb-2012 - Panu Miettinen, 43, has been appointed Chief Financial Officer (CFO) of Biotie Therapies Corp., effective March 15, 2012. He will become a member of the Group's management team and will report to Timo Veromaa, President and Chief Executive Officer. Panu Miettinen will be based at the Company's ...

appointments

US National Institute on Drug Abuse (NIDA) to Conduct Clinical Study on Biotie's Nepicastat in Cocaine Dependence

15-Dec-2011 - Biotie Therapies announced that it has signed a Collaborative Research and Development Agreement with the National Institute on Drug Abuse (NIDA) at the US National Institutes of Health.Under the agreement, NIDA and Biotie will investigate the safety and efficacy of Biotie's nepicastat (SYN117) ...

cocaine addiction drug abuse
Search all
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 27,212 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now